Viatris, Inc. Issues Recall of Xanax XR 3 mg Tablets: What You Need to Know
A recent recall of a commonly used drug for anxiety and panic disorders has been issued by Viatris, Inc. The recall affects a single lot of extended-release Xanax XR tablets in 3 mg strength, packaged in 60-tablet bottles and distributed nationwide. The recall was initiated due to the tablets not meeting dissolution specifications, potentially affecting the dosage consistency over time. The FDA has classified this recall as Class II, indicating a low probability of serious adverse health consequences. The recall is limited to the specific lot of Xanax XR, and most patients in the U.S. are prescribed generic alprazolam, which is not impacted by this recall.
Pharmacies have been instructed to review their quality assurance and recall policies following the recall. Despite the recall, there have been no reported adverse reactions from patients who have taken the affected tablets. The risk to patients is considered minimal, and there is no need for patients to take any action as the recall is at the retailer level. The recalled tablets were distributed between August 2024 and May 2025. If you have any concerns, it is advisable to consult your physician or pharmacist for guidance.
In conclusion, the voluntary recall of a specific lot of Xanax XR tablets by Viatris, Inc. due to dissolution specifications not being met has prompted pharmacies to review their quality assurance and recall procedures. Patients are reassured that the risk associated with the recalled tablets is minimal, and no adverse reactions have been reported. If you have any concerns, it is recommended to seek advice from your healthcare provider.